D.C. Council Grants Initial Approval To Pharmaceutical Sales Representative Licensing Bill
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Pharmacy / Pharmacist; Primary Care / General Practice
Article Date: 14 Dec 2007 - 7:00 PDT
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
3 (3 votes) |
The Washington, D.C., Council on Tuesday voted 7-6 to grant initial approval for legislation that would require pharmaceutical sales representatives to be licensed, the Washington Post reports. Under the legislation, representatives would be required to have a college degree, sign a code of ethics and be subject to regulation by a pharmacy board. Representatives also would be prohibited from using titles that falsely imply they are licensed to practice pharmacy, medicine or nursing. The bill also includes a ban on a practice known as data mining, where drug makers use doctors' prescribing data without their knowledge to develop marketing strategies.
Industry lobbyists urged the council to reject the bill, saying that federal laws and American Medical Association policies provide adequate oversight of drug representatives. However, council Health Committee Chair David Catania said those laws and policies do not stop representatives from misinforming physicians. If approved, the district would be the first jurisdiction in the U.S. to license pharmaceutical sales representatives, the Post reports.
Pharmaceutical Research and Manufacturers of America Senior Vice President Ken Johnson in a statement on Tuesday said, "The bill passed by the council puts the city into a regulatory arena that has been effectively addressed by federal laws and federal government agencies for years." Johnson added that the legislation "creates unnecessary financial burdens for the District of Columbia at a time when the money would be better spent addressing a wide array of health care challenges confronting the city." The council will vote on final approval of the bill on Jan. 8, 2008 (Stewart, Washington Post, 12/12).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/91780.php>
APA
http://www.medicalnewstoday.com/releases/91780.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




